Bach Pharma is developing patented phthalazinedione formulations to address unmet needs in:
Bach, a privately held and funded pharmaceutical company founded in 2001, is engaged in the discovery, development and commercialization of new therapeutics for the treatment of life threatening oxidative stress-related diseases and other serious illnesses.
- Immunology and Auto-immune Disease
- Wound Care
- Metabolic Syndrome
- Radiation Exposure
Bach has identified and licensed a lead candidate, monosodium α-luminol (GVT®), a phthalazinedione formulation that acts by reversing oxidative stress and by serving as a buffer to restore and maintain redox homeostasis. Bach Pharma’s strategy is to develop GVT® as an adjunct therapeutic agent for commercially large indications, and as a primary treatment for other indications including rare diseases. Bach is seeking to license GVT® with one or more pharmaceutical partners with expertise in research, development, distribution and commercialization of pharmaceuticals in the relevant therapeutic area.
Bach is dedicated to the cardinal principles of scientific excellence and to the highest standards of ethics and integrity. Bach realizes that success depends on creating the environment necessary to nourish integrity, knowledge, imagination, skill, diversity and teamwork in our employees and our strategic partners.
"Enthusiastic member of MBC - Advancing Massachusetts Biotechnology for worldwide medical benefits"
"Proud Intern Challenge Host Company of MLSC"
"Honored Member of USRCCNE - Developing mutual business and cultural opportunities for a regional network of US and Russian chambers of commerce"
"Planning partner for the creation of the US-Russia Scientific Exchange Forum (A Foundation for the National Institutes of Health (FNIH) Partner)"